trial

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

NCTId NCT00419653
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 19 (actual)
Sponsored by University of Jena
Primary completion 2007-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
19 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2003-01
Primary completion
2007-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AmisulprideOlanzapineHaloperidol

Sponsors

University of JenaLead Sponsor
SanofiCollaborator

Investigators

1
Ralf Schlösser, M.D.Principal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
19
Phase
PHASE4
Primary Completion Date
2007-09
Status
TERMINATED
relationships
The graph out of here
drug
Amisulpride
drug
Olanzapine
drug
Haloperidol
drug
lead_sponsor
University of Jena
company
collaborator
Sanofi
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ralf Schlösser, M.D.
person